Highlights of This Issue 1335

COMMENTARY

1337  
Stem Cell Factor LIFted as a Promising Clinical Target for Cancer Therapy  
Yu Shi, Sean Hunter, and Tony Hunter  
See related article, p. 1341

SMALL MOLECULE THERAPEUTICS

1341  
EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic LIFR Signaling in Triple-Negative Breast Cancer  
See related commentary p. 1337

1355  
Combinatorial Therapy of Zinc Metallochaperones with Mutant p53 Reactivation and Diminished Copper Binding  
Saif Zaman, Xin Yu, Anthony F. Bencivenga, Adam R. Blanden, Yue Liu, Tracy Withers, Bing Na, Alan J. Blayney, John Gilleran, David A. Boothman, Stewart N. Loh, S. David Kimball, and Darren R. Carpizo

1366  
Mutant-Selective Irreversible EGFR Inhibitor, Naquotinib, Inhibits Tumor Growth in NSCLC Models with EGFR-Activating Mutations, T790M Mutation, and AXL Overexpression  
Hiroaki Tanaka, Hideki Sakagami, Naoki Kaneko, Satoshi Konagai, Hiroko Yamamoto, Takahiro Matsuya, Masatoshi Yuri, Yosuke Yamanaka, Masahiro Mori, Masahiro Takeuchi, Hiroyuki Koshio, Masaaki Hirano, and Sadao Kuromitsu

1374  
Targeting Mitochondrial Proline Dehydrogenase with a Suicide Inhibitor to Exploit Synthetic Lethal Interactions with p53 Upregulation and Glutaminase Inhibition  
Gary K. Scott, Christina Yau, Beatrice C. Becker, Sana Khatreeb, Sophia Mahoney, Martin Borch Jensen, Byron Hann, Bryan J. Cowen, Scott D. Pegan, and Christopher C. Benz

1386  
A Short SOX9 Peptide Mimics SOX9 Tumor Suppressor Activity and Is Sufficient to Inhibit Colon Cancer Cell Growth  
Philippe Blache, Lucile Canterel-Thourennon, Muriel Busson, Pascal Verdié, Gilles Subra, Marc Ychou, and Corinne Prévostel

LARGE MOLECULE THERAPEUTICS

1396  
 Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers  
Adam Stewart, Elizabeth A. Coker, Sebastian Pölsterl, Alexandros Georgiou, Anna R. Minchom, Suzanne Carreira, David Cunningham, Mary ER. O’Brien, Florence I. Raynaud, Johann S. de Bono, Bissan Al-Lazikani, and Uday Banerji

1405  
Vorinostat Potentiates 5-Fluorouracil/Cisplatin Combination by Inhibiting Chemotherapy-Induced EGFR Nuclear Translocation and Increasing Cisplatin Uptake  
Geny Piro, Maria Serena Roca, Francesca Bruzzese, Carmine Carbione, Federica Iannelli, Alessandra Leone, Maria Grazia Volpe, Alfredo Budillon, and Elena Di Gennaro

1418  
Oncolytic Herpes Virus Armed with Vascularstatin in Combination with Bevacizumab Abrogates Glioma Invasion via the CCN1 and AKT Signaling Pathways  
Yusuke Tomita, Kazuhiko Kurozumi, Ji Young Yoo, Kentaro Fujii, Tomotsugu Ichikawa, Yuji Matsumoto, Atsuhito Uneda, Yosuke Yamanaka, Takeshi Shimizu, Yoshihiro Otani, Tetsuo Oka, Balveen Kaur, and Isao Date

1430  
Sentinel Lymph Node–Targeted Therapy by Oncolytic Sendai Virus Suppresses Micrometastasis of Head and Neck Squamous Cell Carcinoma in an Orthotopic Nude Mouse Model  
Yuya Tanaka, Koji Araki, Shingo Tanaka, Yoshihiro Miyagawa, Hiroshi Suzuki, Daisuke Kamide, Masayuki Tomifuji, Kousuke Uno, Eiko Kimura, Taku Yamashita, Yasuji Ueda, and Akihiro Shiotani

1439  
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer  
Yuping Yin, Weizhen Liu, Qian Shen, Peng Zhang, Lulu Wang, Ruikang Tao, Hang Li, Xianxiong Ma, Xiangyu Zeng, Jae-Ho Cheong, Shumei Song, Jaffer A. Ajani, Gordon B. Mills, Kainxiong Tao, and Guang Peng
COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS

1451 Prognostic and Biologic Relevance of Clinically Applicable Long Noncoding RNA Profiling in Older Patients with Cytogenetically Normal Acute Myeloid Leukemia

MODELS AND TECHNOLOGIES

1460 Identifying Candidate Druggable Targets in Canine Cancer Cell Lines Using Whole-Exome Sequencing
Sunetra Das, Rupa Idate, Kathryn E. Cronise, Daniel L. Gustafson, and Dawn L. Duval

ABOUT THE COVER
The treatment of N0 head and neck squamous cell carcinoma remains controversial between dissecting the neck or watchfully monitoring the condition. To generate a new option, Dr. Tanaka and colleagues developed a urokinase-type plasminogen activator-dependent oncolytic Sendai virus ("Bioknife"). In the cover image, GFP-expressing Bioknife is shown to be present in the tongue after injection into an orthotopic xenograft in mice. The authors further demonstrate Bioknife migrates to the sentinel lymph node where it suppressed lymph node metastasis. Read the full article on page 1430.
# Molecular Cancer Therapeutics

18 (8)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://mct.aacrjournals.org/content/18/8">http://mct.aacrjournals.org/content/18/8</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://mct.aacrjournals.org/content/18/8">http://mct.aacrjournals.org/content/18/8</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>

Downloaded from mct.aacrjournals.org on August 19, 2021. © 2019 American Association for Cancer Research.